Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
That’s news. Where did you find that?
Or it could be that nobody cares about your poll!
She’s probably on meds!
This is not a new attack and it’s coming from a guy who is the proud owner of the failed STRENGTH trial. Does he have any clinical evidence to support his argument or is he just throwing crap out there hoping it will stick. You sound an awful lot like the guy on Stocktwits this morning throwing out the same nonsense.
People like you!
Oh, okay! Or is that OH, OKAY!!!!!!????
As an employee or a client?
You know what’s pathetic? People who respond to their own posts.
I’d like to see GS’s Paul Choi (PT $6) debate Piper’s Yasmeen Rahini (PT $19) since both of their reports are based on the Q1 results.
How many ways can Amarin spend money without making a connection with Vascepa? I can’t imagine Henry Ford promoting the virtues of the internal combustion engine and vehicular travel without mentioning the Model A. Hopefully, KM has a better understanding than the current collection of paycheck recipients.
Thin skins! If they were doing a good job they wouldn’t care about criticism. And the fact that they censure posters is an admission that they know how bad they are.
No Confidence! It's hard to believe that the market has less confidence in Mikhail than it did in Thero. What does the market know that we don't about Mikhail being able to lead the company to success? Yee didn't seem to positive, but then again, maybe he saw his "in" with Amarin management drying up and he's just banging on his high chair.
Actually I don’t follow your posts, but it’s good to know you think so highly of yourself.
Does Amarin seem like it’s ready to go belly up? Or is spreading nonsensical FUD your second evening job?
It could be, couldbe, that BP is scratching its collective head wondering why isn’t this drug, that will sell itself, selling itself.
So, if I understand this correctly, Amarin would have had standing and the motion to vacate was only denied because Epadi didn’t have standing? Thanks Amarin.
Merck: hang on a second!
Still snowing in Texas. But seriously, I’d like to see a state by state breakdown of the sales and then ask them why they chose to cite the weather in Texas as one of the reasons sales are flat.
They’re always on defense.
And Kennedy thinks he’s going to be approving attorneys invoices until it’s over.
Does Amarin really need hundreds of salespeople if the scripts are just going to tread water?
Me thinks Du is freaking out. Bungled case. Potentially heard by SCOTUS. Already dealt with an ethics complaint. The noose (can we still say that?) is tightening!
Management is always on defense. They just don’t get it. And they just don’t care.
Nobody held Kennedy responsible, so the culture is spread high and wide.
To buy stuff their kids won’t want!
Doing what to generate revenue?
You missed the point.
If they’re trotting out PRs on a Saturday morning, my guess is somebody got their ass chewed out about taking care of business. Or maybe with the Final Four and The Masters in the rear view mirror, they didn’t have anything else to do this weekend.
I’ll go with “Thero runs such a lean company that he didn’t want to spend the money on hiring someone to do the work.” And, under their breath “when that money would be better spent dishing out perks”!
The worst part of this is they have obviously done nothing in two years that they deem worthy of mentioning in the R&D section of their website. For a one drug company, it’s astounding that they have no interest or commitment to developing a pipeline. They always refer to Vascepa as their “lead” drug. I think they can stop that nonsense now.
How is a guy, hired to launch Europe, in the business for over 20 years, at Amarin for almost a year, not known to "investors"? Especially since Europe became the focus after Kennedy screwed up the U.S. market?
For now. But Yee (I think) claims generics will increase their sources. Of course he whistles past the legal challenges.
It’s not like they still show Mark Saylor in the executive team.
Damn!
Isn’t their issue that they want Du’s application of Graham factors to stand, establishing case law for generics to run rampant over patents? But maybe I should leave the legal stuff to the attorneys!
Busy day?
Or she could be kibitzing with her Hikma overlords!
Not a defense of Thero, because I still think his fatal mistake was trusting Kennedy and allowing Kennedy to take advantage of him by convincing him that his strategery will win the day. But I wonder if Covid hadn’t happened, would he have had more success in getting Vascepa sold giving him some cover for the patent problems? He’s not the only executive to lose his job as a result of the pandemic’s impact.
Like a hawk!
If they're pushing JT out the door, why not just do it? Instead of this nonsensical transition period where the market doesn't really know who's in charge of what, why not let Mikhail jump in and start calling the shots publicly and let JT assume the role of advisor now? But doing anything with a sense of urgency has never been the Thero way, so why start now?